Cadila manufacturing facility in India gets FDA Form 483 for 5 observations

fda
Cadila's Liva subsidiary was hit with a Form 483 by the FDA following an inspection of its plant in Vadodara, India. (FDA)

Liva Pharmaceuticals, a wholly owned manufacturing facility of Indian drugmaker Cadila Healthcare, was hit with a Form 483 (PDF) by the FDA following an inspection of its plant in Vadodara, India.

Regulatory inspectors visited the injectables plant from Aug. 20-28, during which they cited the company for five observations. Issues at the facility included problems with Liva’s product sterility procedures, deficiencies in monitoring environmental conditions, lack of proper training for employees and problems with its record keeping process.

In the Form 483, the agency said inspectors found “containers having obvious breach of container/closure integrity such as cracked container, broken container, containers with missing stopper/closures” that had not been rejected or discarded with appropriate documentation,

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“This was a product specific preapproval inspection,” the company said in a filing with the Bombay Stock Exchange. “It concluded with five observations. Liva will respond to the USFDA with 15 days.”

The company added that the Liva facility does not currently export any products to the U.S. market.